Angiogenesis targeting in lung cancers;Le ciblage de l'angiogenèse dans les cancers du poumon

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Planchard, David ^a   Besse, Benjamin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Lung cancer; VEGF; VEGF R

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CILENGITIDE; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; INTEGRIN; MARIMASTAT; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PRINOMASTAT; SORAFENIB; SQUALAMINE; SUNITINIB; THALIDOMIDE; TN 470; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; EPISTAXIS; HEMATEMESIS; HEMOPTYSIS; HUMAN; HYPERTENSION; IMAGING; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; OPTIMAL DRUG DOSE; PATIENT SELECTION; PROTEINURIA; REVIEW; THROMBOSIS;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 36249032564     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0431     Document Type: Review

References (35)

1. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993 ; 329 : 1848-52.
2. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with of without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer : a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001 ; 93 : 300-8.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 ; 346 : 92-8.
4. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer : seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996 ; 88 : 1210-5.
5. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer : first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991 ; 83 : 417-23.
6. Arriagada R, Bergman B, Dunant A, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004 ; 350 : 351-60.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 ; 353 : 123-32.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355 : 2542-50.
9. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990 ; 82 : 4-6.
10. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer : a systematic review of the literature with meta-analysis. Br J Cancer 2002 ; 87 : 694-701.
11. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 2184-91.
12. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 2544-55.
13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 ; 356 : 125-34.
14. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006 ; 24 : 18S (abstract 7002).
15. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-smalll cell lung cancer. Ann Oncol 2006 ; 17(suppl. 9) : ix218 (abstract 729).
16. Besse B, Gauler T, Fischer B, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administrated once daily or twice daily at 1 250 mg as second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer. Ann Oncol 2006 ; 17(suppl. 9) : ix218-ix219 (abstract 730).
17. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC : follow-up results. J Clin Oncol 2006 ; 24 : 18S (abstract 7016).
18. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC : final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006 ; 24 : 18S (abstract 7000).
19. Nakagawa K, Kiuta K, Shinkai T, et al. A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. J Clin Oncol 2006 ; 24 : 18S (abstract 7067).
20. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer : a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002 ; 20 : 4434-9.
21. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy : Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004 ; 22 : 4683-90.
22. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 842-9.
23. Smylie M, Aboulafia D, Tucker R, Bonomi P, Collier M. Phase III study of the matrix metalloproteinases inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001 ; 20 : 307s (Abstract 1226).
24. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001 ; 28 : 620-5.
25. Pujol JL, Breton JL, Gervais R, et al. A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease SCLC patients after response to chemotherapy : an intergroup study FNCLCC Cleo04 - IFCT 00-01. J Clin Oncol 2006 ; 24 : 18S (abstract 7057).
26. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990 ; 348 : 555-7.
27. Herbst RS, Madden TL, Tran HT, Blumenschein Jr. GR, Meyers CA, Seabrooke LF, et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors : evidence for activity in non-small-cell lung cancer. J Clin Oncol 2002 ; 20 : 4440-7.
28. Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003 ; 9 : 4108-15.
29. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radial Oncol Biol Phys 2006 ; 65 : 1536-43.
30. Evelhoch JL, Lorusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004 ; 10 : 3650-7.
31. Goto H, Yano S, Zhang H, et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocatcinoma in nude mice. Cancer Res 2002 ; 62 : 3711-5.
32. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002 ; 62 : 3408-16.
33. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006 ; 24 : 1491-8.
34. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006 ; 66 : 10073-82.
35. McKeage M. Study Group. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer. J Clin Oncol 2006 ; 24 : 18S (abstract 7102).